Highlights and Quick Summary
- EBIT for the quarter ending June 30, 2023 was $-22.6 Million (a 4.36% increase compared to previous quarter)
- Year-over-year quarterly EBIT increased by 17.74%
- Annual EBIT for 2022 was $-67.6 Million (a 88.64% increase from previous year)
- Annual EBIT for 2021 was $-35.8 Million (a 330.14% increase from previous year)
- Annual EBIT for 2020 was $-8.33 Million (a 51.9% increase from previous year)
- Twelve month EBIT ending June 30, 2023 was $-82.8 Million (a 9.17% increase compared to previous quarter)
- Twelve month trailing EBIT increased by 39.62% year-over-year
Trailing EBIT for the last four month:
30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
---|---|---|---|
$-82.8 Million | $-75.9 Million | $-67.6 Million | $-59.3 Million |
Visit stockrow.com/DSGN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT of Design Therapeutics, Inc.
Most recent EBITof DSGN including historical data for past 10 years.Interactive Chart of EBIT of Design Therapeutics, Inc.
Design Therapeutics, Inc. EBIT for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2023 | $-22.6 | $-21.65 | – | – | – |
2022 | $-19.39 | $-19.19 | $-15.64 | $-13.37 | $-67.59 |
2021 | $-11.13 | $-11.34 | $-7.69 | $-5.68 | $-35.83 |
2020 | $-3.86 | $-2.38 | $-1.46 | $-0.62 | $-8.33 |
2019 | – | – | – | – | $-5.48 |
Business Profile of Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology